Sarepta Therapeutics (SRPT) could meet its revised outlook following a recent cut in its revenue guidance for Elevidys, Oppenheimer said in a Sunday report.

Sarepta cut its Elevidys sales guidance by $550 million at the midpoint in response to heightened caution from patients and caregivers following a patient death, according to the note.

Given the totality of safety and efficacy data, the report said investors are less concerned with the potential for another patient death, seeing recent case as idiosyncratic.

Elevidys being taken off the market is unlikely following supportive comments on cell and gene therapies at the FDA roundtable, the report added.

"We remain confident in management's ability to hit guidance and continue to see shares trading at unique levels we might not see again once overhangs are removed this year," the note said.

Oppenheimer reiterated its outperform rating on the stock and its price target of $123 per share.

Price: 39.95, Change: -3.06, Percent Change: -7.11